March 2023 in “JAAD case reports” Dutasteride and minoxidil helped regrow hair in a woman with breast cancer.
June 2023 in “Sri Lanka Journal of Menopause” 1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
5-ARI therapy may help prevent prostate cancer progression.
9 citations
,
December 2009 in “Cancer Research” Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
1 citations
,
October 2002 in “The Journal of Urology”
22 citations
,
January 2004 in “Dermatology” Topical estrogen helps hair growth in menopausal women with no major side effects.
May 2013 in “UTUPub (University of Turku)” Including androgens in hormone therapy may lower breast cancer risk.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
9 citations
,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
October 2025 in “Journal of the Endocrine Society” The patient was satisfied with hormone therapy, and her epilepsy remained stable.
1 citations
,
September 2012 in “Expert Review of Endocrinology & Metabolism” Androgen replacement therapy can improve libido and mood in women with severe androgen deficiency, but more research is needed on its long-term safety.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
November 2025 in “JAAD Case Reports” Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
31 citations
,
September 2006 in “The Journal of Clinical Endocrinology & Metabolism” Testosterone therapy may slightly improve sexual function in postmenopausal women, but its long-term safety is unknown.